Sep 29, 2025
Drug treatments
- Maria Jose Perez J.1
- 1Institut Imagine
- Team Deleidi
Protocol Citation: Maria Jose Perez J. 2025. Drug treatments. protocols.io https://dx.doi.org/10.17504/protocols.io.j8nlkyn4wg5r/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: September 25, 2025
Last Modified: September 29, 2025
Protocol Integer ID: 228173
Funders Acknowledgements:
ASAP
Abstract
Drug treatments
Troubleshooting
Prepare all drugs according to the manufacturer’s instructions.
Dilute drugs to the specified concentrations in culture medium
Expose human iPSC-derived neurons, astrocytes, and microglia to increasing concentrations of CDDO-Me (CAS number 218600-53-4, Cayman Chemical) at the time points specified in the figure legends.
Expose iPSC-derived microglia to GTTP (CAS number 1131626-47-5; MedChemExpress).
Treat cells with additional compounds as specified:
a) Ultrapure lipopolysaccharides from Escherichia coli O111:B4 (LPS-EB Ultrapure; Catalog number: tlrl-3pelps; InvivoGen).
b) SAM-HCl (CAS number 86867-01-8; Merck).
c) FIDAS V (CAS number 1391934-98-7; MedChemExpress).
d) MCHA (CAS number CDS019932; Sigma-Aldrich).
e) MitoQ (CAS number 845959-50-4; Cayman Chemical).
f) Etoposide (CAS number 33419-42-0; MedChemExpress).
For TAG inhibition, treat cells with a combination of PF-04620110 (DGAT1 inhibitor; CAS number 1109276-89-2, MedChemExpress) and PF-06424439 (DGAT2 inhibitor; CAS number 1469284-78-3, MedChemExpress).
Apply treatments for the specific durations indicated in the figure legends.
Treat control cultures with an equivalent volume of vehicle solvent.